Mandatory notification of trade
Nykode Therapeutics ASA (NYKD) · publisert 28. august 2026 kl. 00:20 · vis på NewsWeb
Transaksjoner
| Person | Rolle | Type | Volum | Pris | Dato | ISIN | Handelsplass |
|---|---|---|---|---|---|---|---|
| Trygve Lauvdal via RASMUSSENGRUPPEN AS | Styremedlem | Kjøp Emisjon/tegning | 7 200 000 | 4,4 NOK | 1 uke siden | NO0010714785 | Outside a trading venue |
| Christian Åbyholm via Norda ASA | Styremedlem | Kjøp Emisjon/tegning | 1 705 000 | 4,4 NOK | 1 uke siden | NO0010714785 | Outside a trading venue |
| Christian Åbyholm via Victoria India Fund AS | Styremedlem | Kjøp Emisjon/tegning | 1 705 000 | 4,4 NOK | 1 uke siden | NO0010714785 | Outside a trading venue |
Vedlegg
- PDMR forms.pdf (application/pdf, originaldokument)
Meldingstekst
28 August 2026
Reference is made to the stock exchange announcement published on 27 August 2026 by Nykode Therapeutics ASA ("Nykode" or the "Company", ticker code "NYKD") regarding the successful placing of a private placement (the "Private Placement") of 65,000,000 new shares in the Company at a subscription price of NOK 4.4 per share (the "Offer Shares").
Please see the attached forms for details on allocation to companies closely associated with primary insiders of the Company.
Disclosure regulation
This information is subject to the disclosure requirements in articles 19 of the Regulation EU 596/2014 (the EU Market Abuse Regulation) and section 5-12 of the Norwegian Securities Trading Act.